Florida to Receive $5 Million in Abbott Labs Settlement

Florida stands to pick up nearly $5 million for future consumer protection efforts from a multistate and federal settlement with Abbott Laboratories over improperly misbranding the anti-seizure drug Depakote, the state attorney general's office announced.

Abbott, as part of an overall $1.6 billion settlement, admitted that despite credible scientific evidence, the drug was promoted in nursing homes for the treatment of dementia between 1998 and 2006, according to the U.S. Justice Department. The drug was also marketed as part of a schizophrenia treatment from 2001 through 2006.

The Food and Drug Administration didn’t approve either use.

Depakote, one of Illinois-based Abbott’s best-selling drugs before its patent expired in 2007, is approved for the treatment of epilepsy, bipolar disorder and migraines.

“Marketing off-label uses for pharmaceutical drugs is dangerous, and this settlement holds Abbott accountable and protects consumers,” Attorney General Pam Bondi stated in a release.

The states and District of Columbia will divide $100 million of the settlement.

The overall settlement, which includes five-year probation for the company, is the second-largest payment by a drug company, trailing only Pfizer Inc.'s $2.3 billion settlement in 2009.
Add a Comment

Comments (1)

Daniel Haszard
3:40PM MAY 8TH 2012
Reg-Abbott labs off-label promotion of Depakote.
I took Depakote for 6 years was ineffective for my condition PTSD,the doctor kept telling me to take it.
The saga of the schizophrenia drugs is one of incredible profit.Eli Lilly made $65 BILLION on Zyprexa franchise. Described as *the most successful drug in the history of neuroscience*.There is a whole underclass block of our society,including children in foster care that are the market for these drugs,but have little voice of protest if harmed by them.
--Daniel Haszard

Leave a Comment on This Story

The content of this field is kept private and will not be shown publicly.
To prevent automated spam submissions leave this field empty.